Premium
Eradication of Helicobacter pylori : recent advances in treatment
Author(s) -
McLoughlin Ramona M.,
O'Morain Colm A.,
O'Connor Humphrey J.
Publication year - 2005
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2005.00340.x
Subject(s) - rifabutin , helicobacter pylori , clarithromycin , levofloxacin , medicine , amoxicillin , proton pump inhibitor , regimen , pharmacotherapy , furazolidone , gastroenterology , helicobacter , antibiotics , intensive care medicine , microbiology and biotechnology , biology
Helicobacter pylori plays a key role in dyspepsia, peptic ulcer disease, and gastric neoplasia and eradication of the infection has become an important treatment goal in clinical practice. Seven‐day proton‐pump inhibitor–amoxicillin–clarithromycin triple therapy is the current first‐line therapy for H. pylori but eradication rates are compromised by poor compliance and antibiotic resistance. Ten‐day sequential treatment may emerge as an alternative first‐line therapy. Bismuth‐based quadruple therapy is the second‐line regimen of choice. Antimicrobial sensitivity testing is not recommended in the routine management of H. pylori infection. Novel triple‐therapy regimens containing rifabutin, levofloxacin, or furazolidone may be useful alternatives as second‐ or third‐line therapy.